Royal Bank Of Canada Cuts Insmed (NASDAQ:INSM) Price Target to $205.00

Insmed (NASDAQ:INSM) had its price objective trimmed by Royal Bank Of Canada from $220.00 to $205.00 in a research report report published on Friday morning,Benzinga reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock.

A number of other research firms also recently issued reports on INSM. Truist Financial set a $205.00 price objective on shares of Insmed in a research note on Monday, January 12th. Wells Fargo & Company lowered their target price on Insmed from $177.00 to $160.00 and set an “overweight” rating for the company in a report on Friday. Jefferies Financial Group initiated coverage on Insmed in a research report on Monday, March 16th. They set a “buy” rating and a $228.00 target price on the stock. Roth Mkm reiterated a “buy” rating and issued a $212.00 price target on shares of Insmed in a report on Friday, April 17th. Finally, Bank of America boosted their price target on Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Insmed currently has a consensus rating of “Buy” and a consensus target price of $211.86.

Insmed Stock Performance

Shares of Insmed stock opened at $101.17 on Friday. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. The stock’s fifty day moving average price is $145.87 and its 200-day moving average price is $165.46. The firm has a market cap of $21.93 billion, a P/E ratio of -17.60 and a beta of 0.89. Insmed has a 12 month low of $64.85 and a 12 month high of $212.75.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.14. The company had revenue of $305.96 million for the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The firm’s quarterly revenue was up 229.7% on a year-over-year basis. During the same period in the prior year, the business earned ($1.42) EPS. On average, equities research analysts expect that Insmed will post -2.41 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Roger Adsett sold 88,060 shares of Insmed stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the completion of the sale, the chief operating officer owned 106,810 shares of the company’s stock, valued at $17,584,130.30. The trade was a 45.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO William Lewis sold 10,699 shares of Insmed stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $143.97, for a total transaction of $1,540,335.03. Following the sale, the chief executive officer owned 301,185 shares of the company’s stock, valued at approximately $43,361,604.45. The trade was a 3.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 161,193 shares of company stock valued at $25,462,012. Insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Insmed

Several institutional investors and hedge funds have recently modified their holdings of the stock. CIBC Private Wealth Group LLC lifted its holdings in Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 53 shares during the period. CoreCap Advisors LLC acquired a new position in Insmed during the fourth quarter worth $27,000. Stone House Investment Management LLC purchased a new position in Insmed in the 3rd quarter valued at about $29,000. SBI Securities Co. Ltd. lifted its position in shares of Insmed by 404.9% in the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 166 shares in the last quarter. Finally, GraniteShares Advisors LLC purchased a new position in Insmed in the 4th quarter valued at $30,000.

Insmed News Roundup

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Insmed reported Q1 EPS of -$0.76, beating estimates, and revenue rose 229.7% year over year to $306 million. The company also reiterated major 2026 commercial goals, including at least $1 billion in BRINSUPRI revenue and $450 million to $470 million in ARIKAYCE revenue. Article: Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts at Royal Bank of Canada and Wells Fargo cut their price targets but kept bullish ratings, signaling they still see meaningful upside from current levels. RBC lowered its target to $205 from $220 and Wells Fargo cut to $160 from $177. Article: Benzinga report on RBC price target cut Article: The Fly report on Wells Fargo price target cut
• Neutral Sentiment: Insmed also highlighted progress on its pipeline and commercialization efforts, including positive ENCORE study results for ARIKAYCE and the start of the PALM-PAH study for TPIP. These updates support the long-term story, but they are less likely to move the stock immediately. Article: Insmed Q1 2026 Financial Results and Business Update
• Negative Sentiment: The stock is under pressure because Q1 sales came in below expectations and the company’s implied 2026 revenue guidance was below consensus, raising concerns that launch momentum may not be matching investor hopes. Article: Insmed’s Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
• Negative Sentiment: Higher first-quarter expenses also weighed on sentiment, with market commentary pointing to increased costs as another reason investors sold the shares after earnings. Article: Insmed Shares Tumble Amid Higher 1Q Expenses

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.